Recently, SGLT-2 inhibitors have also shown robust benefits in HF hospitalizations in patients with HF with reduced ejection fraction regardless of the presence of T2D in the DAPA-HF (dapagliflozin) (25) and EMPEROR-Reduced (empagliflozin) (26) clinical trials. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.